BERKELEY, Calif.--(BUSINESS WIRE)--May 17, 2006--XOMA Ltd. (Nasdaq:XOMA - News) today announced the completion of a letter agreement with Taligen Therapeutics, Inc. of Aurora, CO for the development and cGMP manufacture of a novel antibody fragment for the potential treatment of inflammatory diseases.
